Sarepta touts three-year Duchenne gene therapy data after patient deaths
Sarepta 在患者死亡事件后吹捧三年期杜氏肌营养不良基因疗法数据

Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial.
Sarepta 表示，其杜氏肌营养不良基因疗法在治疗后三年仍保持疗效，依据是来自其关键临床试验受试者的更长期随访结果。